HRP20220669T1 - Supstituirani imidazohinolini kao agonisti tlr7 - Google Patents
Supstituirani imidazohinolini kao agonisti tlr7 Download PDFInfo
- Publication number
- HRP20220669T1 HRP20220669T1 HRP20220669TT HRP20220669T HRP20220669T1 HR P20220669 T1 HRP20220669 T1 HR P20220669T1 HR P20220669T T HRP20220669T T HR P20220669TT HR P20220669 T HRP20220669 T HR P20220669T HR P20220669 T1 HRP20220669 T1 HR P20220669T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- group
- compound
- groups
- solvate
- Prior art date
Links
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- -1 phosphate ester Chemical class 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Spoj opće formule (I):
[image]
gdje
R1 je izabran iz grupe koja se sastoji od -H, C1-6-alkil, C1-6-alkoksi, C1-3-alkoksi-C1-3-alkil, C1-6-alkiltio, C1-3-alkiltio-C1-3-alkil, C1-3-alkilamino-C1-3-alkil, 4- do 10-člane heterocikloalkil, C3-10-cikloalkil, C6-10-aril, C6-10-aril-C1-2-alkil i 5- do 10-članog heteroaril grupe, pri čemu je navedena C1-6-alkil, C1-6-alkoksi, C1-3-alkoksi-C1-3-alkil, C1-6-alkiltio, C1-3-alkiltio-C1-3-alkil, C1-3-alkilamino-C1-3-alkil, C6-10-aril, 4- do 10-člane heterocikloalkil, C3-10-cikloalkil, C6-10-aril-C1-2-alkil i 5- do 10-člana heteroaril grupa izborno supstituirana sa jednom ili sa više grupa koje su neovisno izabrane iz grupe koja se sastoji od C1-4-alkil, -OH, halogene, -CO-N(R4)2, -N(R4)2, -CO-R4, -COO-R4, -N3, -NO2 i -CN grupe;
R2 je izabran iz grupe koja se sastoji od -CO-R5, -CONH-R5 i -COO-R5;
R3 je 1,1-dioksotietan-3-il, koji je izborno supstituiran sa jednom ili sa više grupa koje su neovisno izabrane iz grupe koju čine C1-4-alkil, -OH i halogen;
R4 je svaki neovisno izabran iz grupe koja se sastoji od H i C1-4-alkil;
n je cijeli broj od 3 do 6; i
R5 je izabran iz grupe koja se sastoji od -H, C1-6-alkil, C1-6-alkoksi, C1-3-alkoksi-C1-3-alkil, C1-6-alkiltio, C1-3-alkiltio-C1-3-alkil, C1-3-alkilamino-C1-3-alkil, C6-10-aril, 4- do 10-člane heterocikloalkil, C3-10-cikloalkil i 5- do 10-člane heteroaril grupe, pri čemu je navedena C1-6-alkil, C1-6-alkoksi, C1-3-alkoksi-C1-3-alkil, C1-6-alkiltio, C1-3-alkiltio-C1-3-alkil, C1-3-alkilamino-C1-3-alkil, C6-10-aril, 4- do 10-člana heterocikloalkil, C3-10-cikloalkil i 5- do 10-člana heteroaril grupa izborno supstituirana sa jednom ili sa više grupa koje su neovisno izabrane iz grupe koja se sastoji od C1-4-alkil, -OH, halogene, -CO-N(R4)2, -N(R4)2, -CO-R4, -COO-R4, -N3, -NO2 i -CN grupe;
ili njegov fiziološki funkcionalni derivat, solvat ili sol,
pri čemu je fiziološki funkcionalan derivat prolijek navedenog spoja, gdje je najmanje jedna od sljedećih grupa derivatizirana kao što je navedeno u sljedećem:
(i) grupa karboksilne kiseline (-COOH) je derivatizirana u ester formule -COOR8, gdje je R8 izabran iz grupe koja se sastoji od -H, alkil, alkoksi, alkoksialkil, alkiltio, alkiltioalkil, alkilaminoalkil, aril, heterocikloalkil, cikloalkil i heteroaril grupe, pri čemu su navedene alkil, alkoksi, alkoksialkil, alkiltio, alkiltioalkil, alkilaminoalkil, aril, heterocikloalkil, cikloalkil i heteroaril grupe izborno supstituirane sa jednom ili sa više grupa koje su neovisno izabrane grupa iz grupe koja se sastoji od C1-4-alkil, -OH, halogene, -CO-N(R9)2, -N(R9)2, -CO-R9, -COO-R9, -N3, -NO2 i -CN grupe, pri čemu je svaki R9 neovisno izabran iz grupe koja se sastoji od H i C1-4-alkil;
(ii) hidroksilna (-OH) grupa se derivatizira u ester koji ima formulu -COOR8;
(iii) karboksilna kiselina se derivatizira u amid koji ima formulu -CONH-R8;
(iv) amin (-NH2) se derivatizira u amid koji ima formulu -CONH-R8; i
(v) hidroksilna grupa se derivatizira u fosfatni ester formule -OP(O)(OR10)2, gdje je svaki R10 neovisno izabran iz grupe koja se sastoji od H i C1-4-alkil.
2. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema patentnom zahtjevu 1, gdje je R1 izabran iz grupe koja se sastoji od C1-6-alkil, C1-3-alkoksi-C1-3-alkil, C1-3-alkiltio-C1-3-alkil i C1-3-alkilamino-C1-3-alkil grupe, pri čemu je navedena C1-6-alkil, C1-3-alkoksi-C1-3-alkil, C1-3-alkiltio-C1-3-alkil ili C1-3-alkilamino-C1-3-alkil grupa izborno supstituirana sa jednom ili sa više grupa koje su neovisno izabrane iz grupe koja se sastoji od -OH i halogena.
3. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema patentnom zahtjevu 2, gdje je R1 izabran iz grupe koja se sastoji od C1-6-alkil, C1-3-alkoksi-C1-3-alkil i C1-3-alkilamino-C1-3-alkil grupe, pri čemu je navedena C1-6-alkil, C1-3-alkoksi-C1-3-alkil ili C1-3-alkilamino-C1-3-alkil grupa izborno supstituirana sa jednom ili sa više grupa koja je neovisno izabrana iz grupe koja se sastoji od -OH i halogena.
4. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema bilo kojem od patentnih zahtjeva od 1 do 3, gdje je R1 izabran iz grupe koja se sastoji od etil, metil, propil, butil, metoksietil i etilaminometil grupe, od kojih je svaka izborno supstituirana sa jednom ili više grupa koje su neovisno izabrane iz grupe koja se sastoji od -OH i halogena.
5. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema bilo kojem od patentnih zahtjeva od 1 do 4, gdje je R2 izabran iz grupe koja se sastoji od -CO-R5, -COO-R5 i -CONH-R5.
6. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema patentnom zahtjevu 5, gdje je R2 izabran iz grupe koja se sastoji od -COR5 i -CONH-R5.
7. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema patentnom zahtjevu 5 ili 6, gdje je R2 -CO-R5.
8. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema bilo je od patentnih zahtjeva od 1 do 7, gdje je R3 nesupstituiran 1,1-dioksotietan-3-il.
9. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema bilo kojem od patentnih zahtjeva od 1 do 8, gdje je n cijeli broj od 3 do 5.
10. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema patentnom zahtjevu 9, gdje je n 4.
11. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema bilo kojem od patentnih zahtjeva od 1 do 10, izabrano iz grupe koja se sastoji od :
N-(4-(4-amino-2-etil-1H-imidazo[4,5-c]hinolin-1-il)butil)-N-(1,1-dioksidotietan-3-il)acetamida;
metil (4-(4-amino-2-etil-1H-imidazo[4,5-c]hinolin-1-il)butil)(1,1-dioksidotietan-3-il)karbamata;
1-(4-(4-amino-2-etil-1H-imidazo[4,5-c]hinolin-1-il)butil)-1-(1,1-dioksidotietan-3-il)uree;
N-(4-(4-amino-2-((etilamino)metil)-1H-imidazo[4,5-c]hinolin-1-il)butil)-N-(1,1-dioksidotietan-3-il)acetamida;
metil (4-(4-amino-2-((etilamino)metil)-1H-imidazo[4,5-c]hinolin-1-il)butil)(1,1-dioksidotietan-3-il)karbamata;
1-(4-(4-amino-2-((etilamino)metil)-1H-imidazo[4,5-c]hinolin-1-il)butil)-1-(1,1-dioksidotietan-3-il)uree;
N-(4-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]hinolin-1-il)butil)-N-(1,1-dioksidotietan-3-il) acetamida;
metil (4-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]hinolin-1-il)butil)(1,1-dioksidotietan-3-il)karbamata;
1-(4-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]hinolin-1-il)butil)-1-(1,1-dioksidotietan-3-il)uree;
i njihovih fiziološki funkcionalnih derivata, solvata ili soli.
12. Farmaceutska kompozicija koja sadrži spoj, fiziološki funkcionalni derivat, njegov solvat ili sol prema bilo kojem od patentnih zahtjeva od 1 do 11 i jedan ili više farmaceutski prihvatljivih ekscipijenasa.
13. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema bilo kojem od patentnih zahtjeva od 1 do 11, ili farmaceutska kompozicija prema patentnom zahtjevu 12, za uporabu u vidu medikamenta.
14. Spoj, njegov fiziološki funkcionalni derivat, solvat ili sol prema bilo kojem od patentnih zahtjeva od 1 do 11, ili farmaceutska kompozicija prema patentnom zahtjevu 12, za uporabu u liječenju ili prevenciji medicinskog stanja izabranog iz grupe koja se sastoji od proliferativnih bolesti.
15. Spoj, fiziološki funkcionalni derivat, njegov solvat ili sol ili farmaceutska kompozicija za uporabu prema patentnom zahtjevu 14, pri čemu je medicinsko stanje rak.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017072353 | 2017-09-06 | ||
| EP18769603.4A EP3679025B8 (en) | 2017-09-06 | 2018-08-31 | Substituted imidazoquinolines as agonists of tlr7 |
| PCT/EP2018/073485 WO2019048353A1 (en) | 2017-09-06 | 2018-08-31 | SUBSTITUTED IMIDAZOQUINOLINES AS TLR7 AGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220669T1 true HRP20220669T1 (hr) | 2022-08-19 |
Family
ID=63586658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220669TT HRP20220669T1 (hr) | 2017-09-06 | 2018-08-31 | Supstituirani imidazohinolini kao agonisti tlr7 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11279684B2 (hr) |
| EP (2) | EP3679025B8 (hr) |
| JP (1) | JP7304848B2 (hr) |
| KR (1) | KR20200050964A (hr) |
| CN (1) | CN111132969B (hr) |
| AU (1) | AU2018329152B2 (hr) |
| BR (1) | BR112020004505A2 (hr) |
| CA (1) | CA3074611A1 (hr) |
| DK (1) | DK3679025T3 (hr) |
| ES (1) | ES2914800T3 (hr) |
| HR (1) | HRP20220669T1 (hr) |
| HU (1) | HUE058995T2 (hr) |
| IL (1) | IL273039B2 (hr) |
| LT (1) | LT3679025T (hr) |
| MX (1) | MX2020002366A (hr) |
| PL (1) | PL3679025T3 (hr) |
| PT (1) | PT3679025T (hr) |
| RS (1) | RS63265B1 (hr) |
| SG (1) | SG11202001926QA (hr) |
| SI (1) | SI3679025T1 (hr) |
| WO (1) | WO2019048353A1 (hr) |
| ZA (2) | ZA202001267B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4257198A3 (en) | 2017-08-22 | 2023-10-18 | Dynavax Technologies Corporation | Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof |
| WO2019048036A1 (en) * | 2017-09-06 | 2019-03-14 | Biontech Ag | SUBSTITUTED IMIDAZOQUINOLINES |
| SG11202108752YA (en) * | 2019-03-07 | 2021-09-29 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
| JP2023533961A (ja) * | 2020-07-08 | 2023-08-07 | パーデュー・リサーチ・ファウンデーション | 線維性疾患およびがんを処置するための化合物、組成物、および方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| MY157827A (en) | 2003-06-27 | 2016-07-29 | 3M Innovative Properties Co | Sulfonamide substituted imidazoquinolines |
| EP1686992A4 (en) | 2003-11-25 | 2009-11-04 | 3M Innovative Properties Co | HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME |
| PT2276486E (pt) | 2008-03-24 | 2013-12-04 | 4Sc Discovery Gmbh | Novas imidazoquinolinas substituídas |
| AU2016317637B2 (en) | 2015-08-31 | 2019-01-31 | Solventum Intellectual Properties Company | Guanidine substituted imidazo[4,5-c] ring compounds |
| WO2019048036A1 (en) * | 2017-09-06 | 2019-03-14 | Biontech Ag | SUBSTITUTED IMIDAZOQUINOLINES |
-
2018
- 2018-08-31 SI SI201830679T patent/SI3679025T1/sl unknown
- 2018-08-31 CN CN201880057607.XA patent/CN111132969B/zh active Active
- 2018-08-31 WO PCT/EP2018/073485 patent/WO2019048353A1/en unknown
- 2018-08-31 LT LTEPPCT/EP2018/073485T patent/LT3679025T/lt unknown
- 2018-08-31 PT PT187696034T patent/PT3679025T/pt unknown
- 2018-08-31 MX MX2020002366A patent/MX2020002366A/es unknown
- 2018-08-31 EP EP18769603.4A patent/EP3679025B8/en active Active
- 2018-08-31 HR HRP20220669TT patent/HRP20220669T1/hr unknown
- 2018-08-31 EP EP22169256.9A patent/EP4098652A1/en active Pending
- 2018-08-31 PL PL18769603T patent/PL3679025T3/pl unknown
- 2018-08-31 ES ES18769603T patent/ES2914800T3/es active Active
- 2018-08-31 HU HUE18769603A patent/HUE058995T2/hu unknown
- 2018-08-31 US US16/644,079 patent/US11279684B2/en active Active
- 2018-08-31 CA CA3074611A patent/CA3074611A1/en active Pending
- 2018-08-31 BR BR112020004505-5A patent/BR112020004505A2/pt unknown
- 2018-08-31 JP JP2020513788A patent/JP7304848B2/ja active Active
- 2018-08-31 KR KR1020207006141A patent/KR20200050964A/ko not_active Application Discontinuation
- 2018-08-31 IL IL273039A patent/IL273039B2/en unknown
- 2018-08-31 RS RS20220493A patent/RS63265B1/sr unknown
- 2018-08-31 SG SG11202001926QA patent/SG11202001926QA/en unknown
- 2018-08-31 DK DK18769603.4T patent/DK3679025T3/da active
- 2018-08-31 AU AU2018329152A patent/AU2018329152B2/en active Active
-
2020
- 2020-02-27 ZA ZA2020/01267A patent/ZA202001267B/en unknown
-
2021
- 2021-02-26 ZA ZA2021/01323A patent/ZA202101323B/en unknown
-
2022
- 2022-02-10 US US17/669,117 patent/US11987569B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220669T1 (hr) | Supstituirani imidazohinolini kao agonisti tlr7 | |
| RS54166B1 (en) | IMIDASO [1,2-A] Pyridine derivatives as FGFR kinase inhibitors for use in therapy | |
| HRP20180447T1 (hr) | Derivati kinazolina za liječenje virusnih infekcija i drugih bolesti | |
| CY1124284T1 (el) | Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53 | |
| IL273002B2 (en) | Transmuted imidazoquinolines | |
| HRP20171078T1 (hr) | Derivati arilmetoksi izoindolina i pripravci koji ih sadrže, te postupci njihove uporabe | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| HRP20171638T1 (hr) | Derivati pirazolin diona kao inhibitori nadph oksidaze | |
| HRP20160002T1 (hr) | Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze | |
| MX2024004790A (es) | Esteroides neuroactivos y sus metodos de uso. | |
| HRP20130900T1 (hr) | Derivat (aza)indola i njegova uporaba u medicinske svrhe | |
| EA200800781A1 (ru) | АМИДНЫЕ И КАРБАМАТНЫЕ ПРОИЗВОДНЫЕ АЛКИЛЗАМЕЩЕННЫХ N-[4-(4-АМИНО-1Н-ИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)БУТИЛ]МЕТАНСУЛЬФОНАМИДОВ И СПОСОБЫ | |
| HRP20140501T1 (hr) | Derivati benzazepina korisni kao antagonisti vazopresina | |
| HRP20230854T1 (hr) | Fap-aktivirana terapeutska sredstva i s njima povezane uporabe | |
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
| AR039965A1 (es) | Compuestos aza espiro condensados, composiciones farmaceuticas y su uso para tratamiento de trastornos del sistema nervioso central | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| ME01312B (me) | Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze | |
| WO2004076386A3 (en) | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors | |
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| BR0109469A (pt) | Compostos derivados de b-aminoácidos, composição farmacêutica, método para o tratamento ou prevenção de disfunções inflamatórias, método para o tratamento de condições ou doenças mediadas por mmps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso do composto | |
| RS54258B1 (en) | SRC / ABL INHIBITOR FORMULATIONS |